kabutan

Astellas Pharma Inc.(4503) Summary

4503
TSE Prime
Astellas Pharma Inc.
2,361.5
JPY
-11.0
(-0.46%)
Mar 13, 3:30 pm JST
14.81
USD
Mar 13, 2:30 am EDT
Result
PTS
outside of trading hours
2,370
Mar 13, 11:34 pm JST
Summary Chart Historical News Financial Result
PER
16.9
PBR
2.40
Yield
3.30%
Margin Trading Ratio
30.74
Stock Price
Mar 13, 2026
Opening Mar 13, 9:00 am
2,331.5 JPY 14.64 USD
Previous Close Mar 12
2,372.5 JPY 14.92 USD
High Mar 13, 10:39 am
2,392.0 JPY 15.03 USD
Low Mar 13, 9:00 am
2,331.0 JPY 14.63 USD
Volume
5,932,700
Trading Value
0.01T JPY 0.09B USD
VWAP
2356.07 JPY 14.78 USD
Minimum Trading Value
236,150 JPY 1,481 USD
Market Cap
4.27T JPY 0.03T USD
Number of Trades
6,469
Liquidity & Number of Trades
As of Mar 13, 2026
Liquidity
High
1-Year Average
6,809
1-Year High Feb 5, 2026
25,789
Margin Trading
Date Short Interest Long Margin Positions Ratio
Mar 6, 2026 605,500 976,600 1.61
Feb 27, 2026 692,300 790,000 1.14
Feb 20, 2026 621,500 928,500 1.49
Feb 13, 2026 645,700 855,800 1.33
Feb 6, 2026 617,800 1,002,600 1.62
Company Profile
Astellas Pharma Inc. is the second-largest pharmaceutical company in Japan, specializing in innovative drugs. The company has particular strengths in urology and transplantation, and is focusing on anticancer drugs.
Sector
Pharmaceuticals
Astellas Pharma Inc. was formed in 2005 through the merger of Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical. The company's main business is the research and development, manufacturing, and sales of pharmaceuticals, with operations spanning globally. In research and development, Astellas focuses on cutting-edge fields such as regenerative medicine and gene therapy, primarily through its U.S. subsidiaries. The company has 11 production sites worldwide, including in Ireland, the Netherlands, and China. Its sales network covers approximately 70 countries where it conducts direct sales, including the United States, Germany, China, France, Spain, and South Korea. Astellas has established an integrated pharmaceutical business across its group, collaborating with regional affiliates to supply raw materials and products. The company operates in a single business segment - pharmaceuticals - leveraging its global R&D infrastructure and sales network for business expansion.